Insulin U-500 in severe insulin resistance in type 2 diabetes mellitus
- 1Department of Diabetes and Endocrinology, University Hospitals of Leicester NHS Trust, Leicester, UK
- 2University of Leicester, Department of Cardiovascular Sciences, Leicester, UK
- J Jarvis, University Hospitals of Leicester NHS Trust, Diabetes Research, Level 1, Victoria Building, Leicester Royal Infirmary, Infirmary Square, Leicester LE1 5WW, UK; janet.jarvis{at}uhl-tr.nhs.uk
- Received 18 July 2008
- Accepted 10 February 2009
Abstract
Some patients with type 2 diabetes mellitus (T2DM) are profoundly insulin resistant and require large insulin doses to achieve optimal glycaemic control. However, large volumes of subcutaneous conventional U-100 insulin can cause discomfort at the injection site, resulting in poor concordance with insulin therapy. One therapeutic option is the use of U-500 insulin, thus reducing the insulin volume by 80%. This review will address the practical issues associated with the use of U-500, clinical efficacy and safety aspects of this concentrated insulin, which has an important role in a subgroup of patients with T2DM.
Footnotes
-
Competing interests: None declared.









